Michael N Dworzak
Overview
Explore the profile of Michael N Dworzak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
1419
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schinnerl D, Riebler M, Schumich A, Haslinger S, Brambock A, Inthal A, et al.
Blood Cancer J
. 2024 Jul;
14(1):119.
PMID: 39039054
No abstract available.
2.
Bertrums E, de Kanter J, Derks L, Verheul M, Trabut L, van Roosmalen M, et al.
Nat Commun
. 2024 Jul;
15(1):6025.
PMID: 39019934
Therapy-related myeloid neoplasms (t-MN) arise as a complication of chemo- and/or radiotherapy. Although t-MN can occur both in adult and childhood cancer survivors, the mechanisms driving therapy-related leukemogenesis likely vary...
3.
Maurer-Granofszky M, Kohrer S, Fischer S, Schumich A, Nebral K, Larghero P, et al.
Haematologica
. 2024 Jul;
109(7):2379-2381.
PMID: 38946650
No abstract available.
4.
Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia
van Weelderen R, Harrison C, Klein K, Jiang Y, Abrahamsson J, Alonzo T, et al.
Blood Adv
. 2024 Apr;
8(12):3200-3213.
PMID: 38621200
A comprehensive international consensus on the cytogenetic risk-group stratification of KMT2A-rearranged (KMT2A-r) pediatric acute myeloid leukemia (AML) is lacking. This retrospective (2005-2016) International Berlin-Frankfurt-Münster Study Group study on 1256 children...
5.
Buldini B, Varotto E, Maurer-Granofszky M, Gaipa G, Schumich A, Bruggemann M, et al.
Blood
. 2024 Jan;
143(17):1738-1751.
PMID: 38215390
In the effort to improve immunophenotyping and minimal residual disease (MRD) assessment in acute lymphoblastic leukemia (ALL), the international Berlin-Frankfurt-Münster (iBFM) Flow Network introduced the myelomonocytic marker CD371 for a...
6.
Kowarsch F, Maurer-Granofszky M, Weijler L, Wodlinger M, Reiter M, Schumich A, et al.
Cytometry A
. 2023 Sep;
105(1):24-35.
PMID: 37776305
T-lineage acute lymphoblastic leukemia (T-ALL) accounts for about 15% of pediatric and about 25% of adult ALL cases. Minimal/measurable residual disease (MRD) assessed by flow cytometry (FCM) is an important...
7.
Rubio-San-Simon A, van Eijkelenburg N, Hoogendijk R, Hasle H, Niemeyer C, Dworzak M, et al.
Paediatr Drugs
. 2023 Sep;
25(6):719-728.
PMID: 37695474
Background: Advanced myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML) are rare hematological malignancies in children. A second allograft is recommended if a relapse occurs after hematopoietic stem cell transplantation,...
8.
Maurer-Granofszky M, Kohrer S, Fischer S, Schumich A, Nebral K, Larghero P, et al.
Haematologica
. 2023 Jun;
109(3):740-750.
PMID: 37345487
Pediatric acute myeloid leukemia (AML) is a highly heterogeneous disease making standardized measurable residual disease (MRD) assessment challenging. Currently, patient-specific DNA-based assays are only rarely applied for MRD assessment in...
9.
van Weelderen R, Klein K, Harrison C, Jiang Y, Abrahamsson J, Arad-Cohen N, et al.
J Clin Oncol
. 2023 Mar;
41(16):2963-2974.
PMID: 36996387
Purpose: A previous study by the International Berlin-Frankfurt-Münster Study Group (I-BFM-SG) on childhood -rearranged (-r) AML demonstrated the prognostic value of the fusion partner. This I-BFM-SG study investigated the value...
10.
Poyer F, Heredia R, Novak W, Zeitlhofer P, Nebral K, Dworzak M, et al.
Front Immunol
. 2022 Jul;
13:869047.
PMID: 35812385
We report the case of a male Pakistani patient with a pathogenic homozygous loss of function variant in the non-homologous end-joining factor 1 () gene. The growth retarded and microcephalic...